---
title: "Comparative effectiveness and personalized medicine research using real-world data"
author: "Thomas Debray, PhD"
format:
  revealjs: 
    transition: none
    smaller: true
    controls: true
    slide-number: false
    chalkboard: 
      buttons: false
    preview-links: auto
    margin: 0.2
    logo: ../_assets/images/copyright.svg
    header-logo: ../_assets/images/smartdata-logo.png
    hide-from-titleSlide: "all"
    theme: ../_assets/styles/slide-styles.scss
    footer: <https://fromdatatowisdom.com/>
    css: ../_assets/styles/additional-styles.css
filters: 
  - ../reveal-header
title-slide-attributes: 
  data-background-image: ../_assets/images/smartdata-logo.png
  data-background-size: 30%
  data-background-position: 2% 2%
---

------------------------------------------------------------------------

### Background

::: columns
::: {.column width="20%"}
![](images/GETREAL.jpg)
:::

::: {.column width="80%"}
IMI GetReal: Incorporating real-life clinical data into drug development
:::
:::

-   GetReal aimed to show how robust new methods of real-world evidence collection and synthesis could be adopted earlier in pharmaceutical research and development and the healthcare decision-making process.
-   Together with Bern, we investigated statistical methods for network meta-analysis

------------------------------------------------------------------------

### ISCB Utrecht

![](images/getreal_2015.jpeg)

------------------------------------------------------------------------

### Introduction

Randomization evenly distributes measured and unmeasured factors among intervention groups and thereby

-   Facilitates identification of causal relationships
-   Avoids bias and confounding
-   Offers a framework for assessing efficacy

The results of randomized, controlled trials are considered to be evidence of the highest grade

------------------------------------------------------------------------

### The Hierarchy of Evidence Pyramid

![](images/evidence_hierarchy.png)

::: aside
'Hierarchy of Evidence Pyramid' adapted from EBP & the Medical Librarian training manual, Duke University 2019, and Online EBM Page Generator, Dartmouth College and Yale University 2019, under the license CC-BY-NC and 113P.
:::

------------------------------------------------------------------------

### Limitations of randomized trials

::: columns
::: {.column width="50%"}
![](images/black_why_1996.png) ![](images/egger_getreal_2016.png)
:::

::: {.column width="50%"}
![](images/frieden_evidence_2017.png)
:::
:::

------------------------------------------------------------------------

### Limitations of randomized trials

-   Experimentation may be unnecessary
-   Experimentation may be inappropriate
-   Experimentation may be impossible
-   Experimentation may be inadequate

::: aside
Black N. BMJ. 1996 May 11;312(7040):1215--8.
:::

------------------------------------------------------------------------

### The efficacy-effectiveness gap

Variability in drug response may arise due to

-   Heterogeneity in case-mix (e.g., comorbidities)
-   Heterogeneity in concomitant medications
-   Heterogeneity in treatment adherence
-   Heterogeneity in prescription behaviour

::: aside
Eichler HG, et al.Nat Rev Drug Discov. 2011 Jul 1;10(7):495--506.
:::

------------------------------------------------------------------------

### The efficacy-effectiveness gap

> Information from RCTs can only answer a minuscule fraction of the near-infinite number of questions about subpopulations, interactions, treatment settings, effects, etc., that are relevant to patients and healthcare professionals at the point of care

::: aside
Eichler H, et al. Clin Pharmacol Ther. 2021 May;109(5):1212--8.
:::

------------------------------------------------------------------------

# Real-world data and Real-world evidence

------------------------------------------------------------------------

### Randomized trials and real-world data

-   The Achilles heel of experimental studies is **sample size** and the **lack of random selection**
-   The Achilles heel of observational studies is error due to **imbalance** in (un)observed variables

> ''Real-world data can improve our understanding of health and social care delivery, patient health and experiences, and the effects of interventions on patient and system outcomes in routine settings'' (NICE)

------------------------------------------------------------------------

### What is real-world data (RWD)?

::: columns
::: {.column width="30%"}
![](images/fda.png)
:::

::: {.column width="70%"}
Data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources
:::
:::

::: columns
::: {.column width="30%"}
![](images/ema.svg)
:::

::: {.column width="70%"}
Routinely collected data relating to a patient's health status or the delivery of health care from a variety of sources other than traditional clinical trials
:::
:::

::: columns
::: {.column width="30%"}
![](images/NICE.png)
:::

::: {.column width="70%"}
Data collected outside the context of a highly controlled clinical trial
:::
:::

------------------------------------------------------------------------

### What is real-world data (RWD)?

RWD is commonly understood as observational data

-   Primary use of data (e.g., data collected in an observational study, data collected with digital wearable devices or patients' or physicians' surveys)
-   Secondary use of data (e.g., electronic healthcare records, claims data, registries)
-   A combination of both

------------------------------------------------------------------------

### Sources of real-world data

```{r}
#| echo: false
#| warning: false
library(ggplot2)
library(dplyr)
library(forcats)

sourcesRWD <- data.frame(RWDsource = c("EHR from primary care",
                                       "EHR from secondary care",
                                       "Medical records from primary care",
                                       "Hospital Data",
                                       "Claims data"
                                       ), 
                         Count = c(8/63,
                                   8/63,
                                   8/63,
                                   20/63,
                                   5/63),
                         Type = "Marketing authorization applications (N=63)")

sourcesRWD <- sourcesRWD %>% add_row(sourcesRWD <- data.frame(RWDsource = c("EHR from primary care",
                                       "EHR from secondary care",
                                       "Medical records from primary care",
                                       "Hospital Data",
                                       "Claims data"
                                       ), 
                         Count = c(2/28,
                                   0/28,
                                   5/28,
                                   7/28,
                                   2/28),
                         Type = "Extensions of indication (N=28)"))

ggplot(data=sourcesRWD, aes(x=fct_reorder(RWDsource, Count),y=Count)) +
  geom_bar(position="dodge",stat="identity") + 
  coord_flip() +
  ylab("") +
  xlab("") +
  facet_wrap(~ Type)
```

::: aside
Flynn R, et al. Clin Pharma and Therapeutics. 2022 Jan;111(1):90--7.
:::

------------------------------------------------------------------------

### Studies generating real-world data

Real-world data is not new in medical decision making

-   Phase IV trials
-   Post-authorisation safety studies (PASS)
-   Post-authorisation efficacy studies (PAES)
-   Studies to measure the effectiveness of risk minimisation measures (RMMs)
-   Studies to support life cycle benefit-risk evaluation

------------------------------------------------------------------------

### How is real-world data used?

-   Explore and quantify the unmet medical need within a particular disease area
-   Derive information on the current standard of care in different jurisdictions
-   Augment or replace the concurrent control of a randomized clinical trial
-   Monitor long-term safety and effectiveness
-   Tailor the usage, schedule and dosage of a treatment to an individual patient's needs

------------------------------------------------------------------------

### What is real-world evidence (RWE)?

Evidence generated from the analysis of real-world data

![](images/reliance_RWD.png)

::: aside
Concato J, Corrigan-Curay J. N Engl J Med. 2022 May 5;386(18):1680--2.
:::

------------------------------------------------------------------------

### How is RWE used?

![](images/brown_use_2019_tbl2.png)

::: aside
Brown JP, et al. BMJ Open. 2019 Oct;9(10):e028133.
:::

------------------------------------------------------------------------

### How is RWE used?

```{r}
#| echo: false
#| warning: false
ggdat <- data.frame(Objective = c("Safety",
                                       "Efficacy",
                                       "Disease Epidemiology",
                                       "Drug Utilization",
                                       "Abuse of drug",
                                       "Other objectives"
                                       ), 
                         Count = c(55/63,
                                   31/63,
                                   5/63,
                                   13/63,
                                   6/63,
                                   8/63),
                         Type = "Marketing authorization applications (N=63)")

ggdat <- ggdat %>% add_row(ggdat <- data.frame(Objective = c("Safety",
                                       "Efficacy",
                                       "Disease Epidemiology",
                                       "Drug Utilization",
                                       "Abuse of drug",
                                       "Other objectives"
                                       ), 
                         Count = c(23/28,
                                   15/28,
                                   3/28,
                                   6/28,
                                   0/28,
                                   3/28),
                         Type = "Extensions of indication (N=28)"))

ggplot(data=ggdat, aes(x=fct_reorder(Objective, Count),y=Count)) +
  geom_bar(position="dodge",stat="identity") + 
  coord_flip() +
  ylab("") +
  xlab("") +
  facet_wrap(~ Type)
```

::: aside
Flynn R, et al. Clin Pharma and Therapeutics. 2022 Jan;111(1):90--7.
:::

------------------------------------------------------------------------

### RWE studies - what is the catch?

-   Selection bias
-   Information bias
-   Confounding

These biases may also appear in clinical trials, for instance when conducting subgroup analysis, principal stratum analysis, or indirect treatment comparisons.

------------------------------------------------------------------------

### Recommendations for RWE studies

![](images/nice_rwe_framework_2022_02.png){width="65%"}

::: aside
NICE real-world evidence framework. National Institute for Health and Care Excellence; 2022 Jun. Report No.: ECD9.
:::

------------------------------------------------------------------------

### Recommendations for RWE studies

![](images/jahanshahi.jpg){width="70%"}

::: aside
Jahanshahi M, et al. Ther Innov Regul Sci. 2021 Sep;55(5):1019--35.
:::

------------------------------------------------------------------------

### Recommendations for RWE studies

![](images/sarri_framework_2020_fig3.jpg)

::: aside
Sarri G, et al. BMJ EBM. 2020 Dec 9;27:109--19.
:::

------------------------------------------------------------------------

### Recommendations for RWE studies

::: columns
::: {.column width="45%"}
```{mermaid}
flowchart TD
  Z[Study planning] --> A(Defining the research question)
  A --> B(Planning study conduct)
  B --> C(Choosing fit-for-purpose data)
  C --> D(Primary data collection)
  C --> E[Study conduct]
  D --> E
```
:::

::: {.column width="55%"}
```{mermaid}
flowchart TD
  Z[Study conduct] --> A(Choosing study design and analytical methods)
  A --> B(Minimising risk of bias)
  B --> C(Assessing robustness of study results)
  C --> D(Using proportionate quality assurance processes)
  D --> E[Study reporting]
```
:::
:::

------------------------------------------------------------------------

### Analysis of RWE studies

Statistical methods for addressing confounding

-   Covariate adjustment
-   Propensity score analysis
-   Prognostic score analysis

These methods are also the building blocks for studies conducting indirect treatment comparisons or incorporating historical controls.

------------------------------------------------------------------------

### Analysis of RWE studies

Many other concerns should be explored:

-   Operational definitions of key study variables
-   Definition of time windows
-   Choice of patient eligibility criteria
-   Missing data and measurement error
-   Alternative model specifications
-   Treatment switching or loss to follow up
-   Non-adherence

------------------------------------------------------------------------

# What is next?

------------------------------------------------------------------------

### Regulatory decision making

![](images/eichler_randomized_2021.png){width="60%"}

-   The future is not about randomized controlled trials (RCTs) ***vs.*** real-world evidence (RWE) but about RCTs ***and*** RWE --- not just for the assessment of safety but also of effectiveness
-   Patients will need to be followed up for prolonged periods of time to empirically confirm or refute *a priori* comparative effectiveness assumptions

------------------------------------------------------------------------

### Requirements

-   Need for additional sources of (non-RCT) evidence
-   Need for better methods for evidence synthesis
-   Need for revised regulatory (and other decision) frameworks

------------------------------------------------------------------------

### Data platforms

::: columns
::: {.column width="30%"}
![](images/darwin-eu-logo.png)
:::

::: {.column width="70%"}
Catalogue of observational data sources for use in medicines regulation
:::
:::

::: columns
::: {.column width="30%"}
![](images/EHDEN_Logo_JPG.jpg)
:::

::: {.column width="70%"}
Federated data network of allowing access to the data of EU citizens standardised to a common data model.
:::
:::

------------------------------------------------------------------------

### Individualizing treatment decisions

-   Causal treatment effects are estimated at the population level in randomised controlled trials (RCTs)
-   However, clinical decision is often to be made at the individual level in practice
-   Individualized absolute treatment effects provide a natural starting point to engage in shared decision making

::: aside
Nguyen TL, et al. J Clin Epidemiol. 2020 May 25;125:47--56.
:::

------------------------------------------------------------------------

### Estimating individualized treatment effects

-   Subgroup analysis is often used to investigate heterogeneity in treatment effects
-   Although subgroup effects can provide interesting insights and generate new hypotheses, they may be difficult to use for guiding treatment
-   It may be more informative to move to the absolute risk scale and estimate multivariable models that adjust for individual patient characteristics

------------------------------------------------------------------------

### Estimating individualized treatment effects

-   Small RCTs
    -   Hard to improve beyond risk-magnification
    -   However, the price to pay to allow for treatment-covariate interactions was small when using both shrinkage and selection, especially for the hierarchical group lasso
-   Large RCTs
    -   Shrinkage and selection still needed
    -   Allowing for all interactions was beneficial

::: aside
Hoogland J, et al. Stat Med. 2021 Nov 20;40(26):5961--81.
:::

------------------------------------------------------------------------

### Estimating individualized treatment effects

::: columns
::: {.column width="50%"}
![](images/hoogland_tutorial_2021.png)
:::

::: {.column width="50%"}
![](images/seo_comparing_2020.png)
:::
:::

::: columns
::: {.column width="50%"}
![](images/efthimiou_measuring_2023.png)
:::

::: {.column width="50%"}
![](images/chalkou_two-stage_2021.png)
:::
:::

------------------------------------------------------------------------

### precmed: Precision Medicine

A doubly robust precision medicine approach to fit, cross-validate and visualize prediction models for the conditional average treatment effect. Available from [GitHub](https://smartdata-analysis-and-statistics.github.io/precmed/) and [CRAN](https://CRAN.R-project.org/package=precmed).

::: columns
::: {.column width="50%"}
![](images/precmed.png)
:::

::: {.column width="50%"}
![](images/precmed_CRAN.png)
:::
:::

------------------------------------------------------------------------

### Comparative effectiveness and personalized medicine using real-world data

-   Edited by TPA Debray, T-L Nguyen and RW Platt
-   21 chapters; publication expected in 2024
-   Contributions from \~ 40 authors (academia; industry; contract resesarch organizations; health technology assessment agencies; regulatory decision-making)
-   Example code on [GitHub](https://smartdata-analysis-and-statistics.github.io/comparative-effectiveness/)

![](images/taylor_francis.png){height="80%"}
